Tuesday, March 31, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Daily Remedy podcast with Aneri Pattani, senior correspondent for KFF Health News

We discuss Miss Pattani’s reporting on opioid settlements, highlighting the advocacy of patients most affected. Through KFF Health News, she leads an initiative to track how opioid settlement funds are allocated.

Miss Aneri Pattani is a national correspondent with KFF Health News, where she reports on a broad range of public health topics, including mental health, substance use, and the health of adolescents and young adults. She is also a fellow at the Bloomberg American Health Initiative.

#opioids #settlements

Relevant articles cited in the podcast include:

https://khn.org/news/article/opioid-drugmakers-settlement-funds-50-billion-dollars-khn-investigation-payback/

https://khn.org/news/article/state-plans-opioid-settlement-funds/

https://khn.org/news/article/rural-america-opioid-settlement-funds-inequity/

https://www.opioidsettlementtracker.com/publicreporting/#promises

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!